203 related articles for article (PubMed ID: 34403034)
1. Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma.
Nanavati C; Mager DE
AAPS J; 2021 Aug; 23(5):101. PubMed ID: 34403034
[TBL] [Abstract][Full Text] [Related]
2. Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells.
Nanavati C; Mager DE
Pharm Res; 2017 Mar; 34(3):668-679. PubMed ID: 28101809
[TBL] [Abstract][Full Text] [Related]
3. Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics.
Niu J; Nguyen VA; Ghasemi M; Chen T; Mager DE
AAPS J; 2021 Oct; 23(6):110. PubMed ID: 34622346
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
5. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
Ramakrishnan V; Mager DE
J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
[TBL] [Abstract][Full Text] [Related]
7. Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
Chudasama VL; Ovacik MA; Abernethy DR; Mager DE
J Pharmacol Exp Ther; 2015 Sep; 354(3):448-58. PubMed ID: 26163548
[TBL] [Abstract][Full Text] [Related]
8. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
[TBL] [Abstract][Full Text] [Related]
9. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
10. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G
Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138
[TBL] [Abstract][Full Text] [Related]
11. Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.
Nanavati C; Ruszaj D; Mager DE
CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):756-764. PubMed ID: 29045072
[TBL] [Abstract][Full Text] [Related]
12. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma.
Ramakrishnan V; Mager DE
CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):146-157. PubMed ID: 30516019
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Pitts TM; Morrow M; Kaufman SA; Tentler JJ; Eckhardt SG
Mol Cancer Ther; 2009 Feb; 8(2):342-9. PubMed ID: 19174560
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT; Richardson P; Lonial S; Orlowski RZ
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):797-803. PubMed ID: 32819881
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
[TBL] [Abstract][Full Text] [Related]
17. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Voorhees PM; Gasparetto C; Moore DT; Winans D; Orlowski RZ; Hurd DD
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):424-432. PubMed ID: 28655599
[TBL] [Abstract][Full Text] [Related]
18. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
19.
Terzi H; Altun A; Şencan M
Indian J Med Res; 2019 Dec; 150(6):630-634. PubMed ID: 32048627
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.
Liao B; Zhang Y; Sun Q; Jiang P
Cancer Med; 2018 Jan; 7(1):196-207. PubMed ID: 29239146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
